The present invention relates to a compound comprising Formula I or IA and an anti-cancer agent in combination, for use in treating a cancer in a mammal in need thereof, the cancer characterized by a KRAS mutation, by an EGFR mutation, and/or by over-expression of AKT2 and wherein the combination produces a synergistic therapeutic effect as compared to sole administration of either the anti-cancer agent or the compound.